Post Exubera#174;: Can New Life be Breathed Back into Inhaled Insulin?
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 92 (Table of Contents)
Published: 1 Feb-2008
DOI: 10.3833/pdr.v2008.i92.221 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
One of the biggest drug delivery stories of 2007 has been the flop of Pfizer#8217;s Exubera#174;, the inhaled insulin product aimed at a multibillion dollar market...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS